C-IG6JHDAC6 inhibition, non-hydroxamate chemotype
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop a selective HDAC6 inhibitor program for chronic disease within Augustine Therapeutics' portfolio targeting neurologic, neuromuscular, and cardiometabolic diseases.
Selective HDAC6 inhibition using Augustine Therapeutics' non-hydroxamate, non-hydrazine producing small-molecule chemotype intended to avoid off-target toxicity while preserving beneficial non-catalytic HDAC6 functions.
Listed in Augustine Therapeutics' pipeline.
Develop a CNS-penetrant HDAC6 inhibitor program for central nervous system disease applications.
Central acting selective HDAC6 inhibition using a CNS-penetrant small-molecule approach based on Augustine Therapeutics' non-hydroxamate, non-hydrazine producing chemotype.
Listed in Augustine Therapeutics' pipeline as a central acting HDAC6 inhibitor program.
Develop a peripherally restricted HDAC6 inhibitor program for peripheral neurologic, neuromuscular, or cardiometabolic disease applications.
Peripherally restricted selective HDAC6 inhibition with Augustine Therapeutics' non-hydroxamate, non-hydrazine producing chemotype.
Listed in Augustine Therapeutics' pipeline as a peripheral HDAC6 inhibitor program.
Create a portfolio of selective HDAC6 inhibitors for chronic diseases while reducing off-target toxicity and preserving beneficial non-catalytic HDAC6 functions.
Novel non-hydroxamate, non-hydrazine producing HDAC6 inhibitor chemistry used to generate peripherally restricted and CNS-penetrant compounds.
Described as the basis for Augustine Therapeutics' advancing peripheral and CNS-penetrant HDAC6 inhibitor programs.